Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging technique could let doctors see lung Cancer's inner workings in real time

NCT ID NCT02676050

Knowledge-focused Sponsor: University of Edinburgh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tested whether two optical imaging agents could be used during a bronchoscopy to visualize activated neutrophils and a cancer-related protein called c-MET in lung tumors. Five participants with lung cancer received the agents through a special catheter while doctors used a miniaturized imaging fiber to detect signals. The goal was to explore whether this technique could provide real-time molecular insights into lung cancer, but the study was terminated early and was not designed to treat the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Optical imaging agents (EMI-137 and NAP)
What this could lead to
If successful, this approach could help doctors see specific cancer-related molecules in real time during a lung exam, potentially improving diagnosis or treatment guidance.
What could go wrong
This was a very small, early exploratory study that was terminated early. It was designed only to test imaging feasibility, not to treat or cure lung cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

5 people

The number who actually took part.

Started

Oct 2019

Finished

Mar 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

INCLUSION CRITERIA FOR COHORT 1 • Patients undergoing cardiothoracic surgery for resection of lung cancer INCLUSION CRITERIA FOR COHORT 2 • Patients with inoperable stage 3 or 4 lung cancer INCLUSION CRITERIA FOR BOTH COHORTS * ≥ 16 years * Provision of informed consent from the patient prior to any study related procedures. * Normal electrocardiogram (ECG) * Forced Expiratory Volume (FEV1) \>1L * Thoracic CT scan taken in the last 20 weeks * Attending consultant permission for bronchoscopy * Readily accessible target areas with bronchoscopy and FE EXCLUSION CRITERIA * Refusal for participation by attending consultant * Unsuitable for bronchoscopy * Any history of anaphylaxis * Significant coagulopathy, which causes bronchoscopy to be unsuitable, as determined by clinical co-investigator or the participant's attending consultant, using information which is routinely available * Myocardial infarction in the preceding four weeks * Women who are pregnant or are breastfeeding * Receiving drugs that cause increased autofluorescence in the lung, specifically amiodorane and methotrexate * Oxygen saturation \<92% breathing room air * Platelet count \< 50 x 109/L * Bleeding diathesis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer

Contacts and locations

Locations

  • Royal Infirmary of Edinburgh

    Edinburgh, EH16 4TJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.